<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;AASLD position paper: the management of acute liver failure: update 2011.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lee WM, Larson AM, Stravitz T. AASLD position paper: the management of acute liver failure: update 2011. Baltimore (MD): American Association for the Study of Liver Diseases; 2011 Sep. 26 p.  [224 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005 May;41(5):1179-97. [179 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Autoimmune hepatitis  (571.42); Budd-chiari syndrome  (453.0); Cerebral edema  (348.5); General physical examination  (89.7); Hemorrhage of gastrointestinal tract, unspecified  (578.9); Hepatic encephalopathy  (572.2); Hyperventilation  (786.01); Insertion of endotracheal tube  (96.04); Malignant neoplasm of liver, not specified as primary or secondary  (155.2); Poisoning by unspecified drug or medicinal substance  (977.9); Renal failure, unspecified  (586)"/><FieldValue Value="MSH: Acetylcysteine ; Acyclovir ; Adrenal Cortex Hormones ; Antibiotic Prophylaxis ; Antifungal Agents ; Bacterial Infections ; Barbiturates ; Benzodiazepines ; Biopsy ; Blood Cell Count ; Blood Chemical Analysis ; Blood Coagulation Tests ; Blood Gas Analysis ; Budd-Chiari Syndrome ; Catheterization, Swan-Ganz ; Charcoal ; Delivery, Obstetric ; Diagnostic Imaging ; Dialysis ; Fatty Liver ; Fluid Therapy ; Gastrointestinal Hemorrhage ; HELLP Syndrome ; Hemolysis ; Hepatic Encephalopathy ; Hepatitis, Autoimmune ; Hepatitis, Viral, Human ; Hepatolenticular Degeneration ; Histamine H2 Antagonists ; Hyperventilation ; Hypothermia, Induced ; Intensive Care ; Intensive Care Units ; Intracranial Hypertension ; Intubation, Intratracheal ; Ischemia ; Lactulose ; Liver Failure, Acute ; Liver Neoplasms ; Liver Transplantation ; Living Donors ; Mannitol ; Medical History Taking ; Mushroom Poisoning ; Mycoses ; Nutrition Assessment ; Penicillin G ; Phenytoin ; Physical Examination ; Pregnancy ; Pregnancy Tests ; Referral and Consultation ; Seizures ; Serologic Tests ; Silymarin ; Sodium Chloride ; Vasoconstrictor Agents "/><FieldValue Value="MTH: Acetylcysteine ; Acyclovir ; Adrenal Cortex Hormones ; Antibiotic Prophylaxis ; Antifungal Agents ; Bacterial Infections ; Barbiturates ; Benzodiazepines ; Biopsy ; blood cell count ; Blood Chemical Analysis ; Blood coagulation tests ; Blood Gas Analysis ; Budd-Chiari Syndrome ; Cerebral Edema ; Diagnostic Imaging ; Drug toxicity ; Fatty Liver ; Fluid Therapy ; Gastrointestinal Hemorrhage ; Hemolysis (disorder) ; Hepatic Encephalopathy ; Hepatic Vein Thrombosis ; Hepatolenticular Degeneration ; Histamine H2 Antagonists ; Hyperventilation ; Hypothermia, Induced ; intensive care ; intensive care unit ; Intracranial Hypertension ; Ischemia ; KIDNEY FAILURE ; Liver neoplasms ; Malignant neoplasm of liver ; Mushroom Poisoning ; Mycoses ; Normal saline ; Nutrition Assessment ; Obstetric Delivery ; Penicillin G ; Phenytoin ; Physical Dialysis ; physical examination ; Pregnancy ; Pregnancy Tests ; Seizures ; Serologic tests ; Sodium Chloride ; Swan-Ganz Catheterization ; Transplantation of liver "/><FieldValue Value="PDQ: acetylcysteine ; acyclovir ; biopsies ; cerebral edema ; coagulation studies ; diagnostic imaging ; drug toxicity ; liver transplantation ; mannitol ; renal failure ; seizure ; silymarin "/><FieldValue Value="SNOMEDCT_US: Acetylcysteine  (387440002); Acetylcysteine  (77731008); Acyclovir  (372729009); Acyclovir  (41193000); Acyclovir  (425884003); Antibiotic prophylaxis  (422181004); Antifungal  (324643005); Antifungal  (373219008); Assessment of nutritional status  (1759002); Assessment of nutritional status  (310243009); Autoimmune hepatitis  (408335007); Bacterial infection by site  (301811001); Bacterial infection by site  (87628006); Barbiturate  (372798009); Barbiturate  (60978003); Benzodiazepine  (16047007); Benzodiazepine  (372664007); Biopsy  (129314006); Biopsy  (86273004); Blood cell count  (88308000); Blood chemistry  (166312007); Blood coagulation panel  (3116009); Blood gas analysis  (167018008); Blood gas analysis  (278297009); Budd-Chiari syndrome  (82385007); Cerebral edema  (2032001); Cerebral pseudosclerosis  (190823004); Cerebral pseudosclerosis  (192640001); Cerebral pseudosclerosis  (88518009); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Delivery - action  (236973005); Delivery - action  (360149000); Fulminant hepatic failure  (197270009); Fulminant hepatic failure  (235884008); Gastrointestinal hemorrhage  (74474003); HELLP syndrome  (95605009); Hepatic encephalopathy  (13920009); Hepatic encephalopathy  (449902003); Hepatic vein thrombosis  (38739001); Histamine H>2< antagonist  (108661002); Histamine H>2< antagonist  (372524001); Hyperventilation  (68978004); Imaging  (363679005); Induction of hypothermia  (308693008); Insertion of endotracheal tube  (112798008); Intensive care unit  (309904001); Ischemia  (52674009); Lactulose  (111137007); Lactulose  (273945008); Live donor  (105456007); Live donor partial hepatectomy  (235462000); Malignant neoplasm of liver  (93870000); Mannitol  (30761007); Mannitol  (387168006); Mycosis  (3218000); Neoplasm of liver  (126851005); Normal saline  (262003004); Penicillin G  (323389000); Penicillin G  (78507004); Phenytoin  (387220006); Phenytoin  (40556005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Poisoning by drug AND/OR medicinal substance  (7895008); Pregnancy  (289908002); Pregnancy detection examination  (74036000); Pulmonary catheterization with Swan-Ganz catheter  (65677008); Raised intracranial pressure  (271719001); Renal failure syndrome  (42399005); Seizure  (91175000); Serologic test  (68793005); Sodium chloride  (387390002); Sodium chloride  (70379000); Transplantation of liver  (18027006); Vasoconstrictor  (372881000); Vasoconstrictor  (8571001)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Acute liver failure (ALF)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Critical Care" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Gastroenterology" /><FieldValue Value="Internal Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide preferred approaches to the diagnostic, therapeutic, and preventive aspects of acute liver failure (ALF) care&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with acute liver failure (ALF)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis/Evaluation/Monitoring&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient history, including exposure to viral infection and drugs and other toxins &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determination of etiology of acute liver failure (ALF) through patient history and laboratory tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Admission to intensive care unit (ICU) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Placement on transplant list, as indicated, and consultation with transplant center &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Liver biopsy, as indicated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring of intracranial pressure and neurological evaluation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Periodic surveillance cultures, to detect bacterial and fungal infections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of prognosis (currently available prognostic scoring systems should not be the sole method) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Management/Treatment by Diagnosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Etiologies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acetaminophen hepatotoxicity&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Activated charcoal and N-acetylcysteine (NAC) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mushroom poisoning&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Penicillin G and NAC &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Placement on transplant list &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Drug-induced liver injury (DILI)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Discontinuation of all but essential medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;NAC &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Viral hepatitis&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Supportive care for types A and E &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nucleos(t)ide analogues for hepatitis B &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Acyclovir herpes virus or varicella zoster &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Wilson disease&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Prompt consideration for transplant with confirmed diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Autoimmune hepatitis&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Corticosteroids (prednisone), as indicated &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consideration for transplant &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acute fatty liver of pregnancy/hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Early delivery &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consideration for transplant, as indicated &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acute ischemic injury&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Cardiovascular support &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Budd-Chiari syndrome&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Liver transplantation &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Malignant infiltration&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Imaging and liver biopsy to confirm or exclude the diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with poor prognosis&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Urgent liver transplantation, as indicated &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Living donor or auxiliary liver transplantation if necessary &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Clinical Features&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Encephalopathy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lactulose, as indicated &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Endotracheal intubation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Phenytoin and short-acting benzodiazepines for seizures (prophylactic phenytoin is not recommended) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mannitol for intracranial hypertension (prophylactic mannitol is not recommended) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Prophylactic induction of hypernatremia for patients at high risk for cerebral edema &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Short-acting barbiturates and induction of hypothermia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Corticosteroids (considered, but not recommended for control of elevated ICP) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Infection&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Prompt initiation of antibiotics at earliest sign of infection &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Prophylactic antibiotics and antifungals (considered but not recommended for most patients) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coagulopathy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Replacement therapy only if hemorrhage is present or prior to invasive procedures &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bleeding&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Prophylactic histamine-2 receptor (H2) blocking agents or proton-pump inhibitors for acid-related gastrointestinal (GI) bleeding &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sucralfate as second-line GI bleeding treatment &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hemodynamics/renal failure&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Intravenous normal saline as initial fluid resuscitation and maintenance of adequate intravascular volume &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Continuous mode dialysis support, as indicated &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pulmonary artery catheterization (considered but not recommended) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Systemic vasopressor support (norepinephrine, vasopressin, or terlipressin), as indicated &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Metabolic concerns&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Maintenance of metabolic homeostasis &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Liver support systems were considered but not recommended outside of clinical trials.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Morbidity and mortality from acute liver failure (ALF) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Predictive value of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness of treatment interventions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Predictive value of prognostic factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;1-year and overall survival rate following transplantation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These recommendations are based on a formal review and analysis of recently published world literature on the topic (Medline/PubMed search from 2000 through 2011). Inclusion criteria were acute liver failure, all ages, both genders, all races, and all etiologies. Specific search terms were 'acute liver failure', 'fulminant hepatic failure', 'fulminant hepatic necrosis', and 'cerebral edema'.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence on Which a Recommendation Is Based&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade I&lt;/strong&gt;: Randomized controlled trials&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-1&lt;/strong&gt;: Controlled trials without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-2&lt;/strong&gt;: Cohort or case-control analytic studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-3&lt;/strong&gt;: Multiple time series, dramatic uncontrolled experiments&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade III&lt;/strong&gt;: Opinions of respected authorities, descriptive epidemiology&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline authors characterized the quality of evidence supporting each recommendation, in accordance with the Practice Guidelines Committee of the American Association for the Study of Liver Diseases (AASLD) recommendations used for full Practice Guidelines (see the &quot;Rating Scheme for the Strength of Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These recommendations provide a data-supported approach. They are based on the following: 1) formal review and analysis of recently-published world literature on the topic (Medline search); 2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines; 3) guideline policies, including the American Association for the Study of Liver Diseases (AASLD) Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association (AGA) Policy Statement on Guidelines; and 4) the experience of the authors in the specified topic.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This position paper was produced in collaboration with the Practice Guidelines Committee of the American Association for the Study of Liver Diseases. This committee provided extensive peer review of the manuscript.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence supporting the recommendations (&lt;strong&gt;Grade I, II-1, II-2, II-3&lt;/strong&gt;, and &lt;strong&gt;III&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis and Initial Evaluation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with acute liver failure (ALF) should be hospitalized and monitored frequently, preferably in an intensive care unit (ICU) (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Contact with a transplant center and plans to transfer appropriate patients with ALF should be initiated early in the evaluation process (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The precise etiology of ALF should be sought to guide further management decisions (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;See Table 2 in the original guideline document for a list of initial laboratory analyses.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Determining Etiologies and Specific Therapies&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Acetaminophen Hepatotoxicity&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;For patients with known or suspected acetaminophen overdose within 4 hours of presentation, give activated charcoal just prior to starting N-acetylcysteine (NAC) (&lt;strong&gt;Grade I&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Begin NAC promptly in all patients where the quantity of acetaminophen ingested, serum drug level, or rising aminotransferases indicate impending or evolving liver injury (&lt;strong&gt;Grade II-1&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;NAC may be used in cases of ALF in which acetaminophen ingestion is possible or when knowledge of circumstances surrounding admission is inadequate but aminotransferases suggest acetaminophen poisoning (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Mushroom Poisoning&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;    &lt;li&gt;In ALF patients with known or suspected mushroom poisoning, consider administration of penicillin G and&amp;nbsp;NAC (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with ALF secondary to mushroom poisoning should be listed for transplantation, as this procedure is often the only lifesaving option (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drug Induced Liver Injury (DILI)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;9&quot;&gt;&#xD;&#xA;    &lt;li&gt;Obtain details (including onset of ingestion, amount, and timing of last dose) concerning all prescription and non-prescription drugs, herbs, and dietary supplements taken over the past year (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determine ingredients of non-prescription medications whenever possible (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the setting of ALF due to possible drug hepatotoxicity, discontinue all but essential medications (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;NAC may be beneficial for ALF due to drug-induced liver injury (&lt;strong&gt;Grade I&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;See Table 3 in the original guideline document for a list of some drugs which may cause idiosyncratic liver injury leading to ALF.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Viral Hepatitis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;13&quot;&gt;&#xD;&#xA;    &lt;li&gt;Viral hepatitis A- and (E-) related ALF must be treated with supportive care as no virus-specific treatment has been proven to be effective (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nucleos(t)ide analogues should be considered for hepatitis B-associated ALF and for prevention of post-transplant recurrence. (&lt;strong&gt;Grade III&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with known or suspected herpes virus or varicella zoster as the cause of ALF should be treated with acyclovir (5-10 mg/kg intravenous [IV] every 8 hours) and may be considered for transplantation (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Wilson Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;16&quot;&gt;&#xD;&#xA;    &lt;li&gt;To exclude Wilson disease one should obtain ceruloplasmin, serum and urinary copper levels, slit lamp examination for Kayser-Fleischer rings, hepatic copper levels when liver biopsy is feasible, and total bilirubin/alkaline phosphatase ratio (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients in whom Wilson disease is the likely cause of ALF must be promptly considered for liver transplantation (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Autoimmune Hepatitis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;18&quot;&gt;&#xD;&#xA;    &lt;li&gt;Liver biopsy is recommended when autoimmune hepatitis is suspected as the cause of ALF, and autoantibodies are negative (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with coagulopathy and mild hepatic encephalopathy due to autoimmune hepatitis may be considered for corticosteroid treatment (prednisone, 40-60 mg/day) (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with autoimmune hepatitis should be considered for transplantation even while corticosteroids are being administered (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Acute Fatty Liver of Pregnancy/Hemolysis, Elevated Liver Enzymes, Low Platelets (HELLP) Syndrome&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;21&quot;&gt;&#xD;&#xA;    &lt;li&gt;For acute fatty liver of pregnancy or the HELLP syndrome, expeditious delivery of the infant is recommended. Transplantation may need to be considered if hepatic failure does not resolve quickly following delivery (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Acute Ischemic Injury&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;22&quot;&gt;&#xD;&#xA;    &lt;li&gt;In ALF patients with evidence of ischemic injury, cardiovascular support is the treatment of choice (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Budd-Chiari Syndrome&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;23&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hepatic vein thrombosis with acute hepatic failure is an indication for liver transplantation, provided underlying malignancy is excluded (&lt;strong&gt;Grade II-3&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Malignant Infiltration&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;24&quot;&gt;&#xD;&#xA;    &lt;li&gt;In patients with ALF who have a previous cancer history or massive hepatomegaly, consider underlying malignancy and obtain imaging and liver biopsy to confirm or exclude the diagnosis (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Indeterminate Etiology&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;25&quot;&gt;&#xD;&#xA;    &lt;li&gt;If the etiological diagnosis remains elusive after extensive initial evaluation, liver biopsy may be appropriate to attempt to identify a specific etiology that might influence treatment strategy (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Therapy: General Considerations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 4 in the original guideline document for specific issues in intensive care of ALF.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Central Nervous System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;26&quot;&gt;&#xD;&#xA;    &lt;li&gt;In early stages of encephalopathy, lactulose may be used either orally or rectally to effect a bowel purge, but should not be administered to the point of diarrhea, and may interfere with the surgical field by increasing bowel distention during liver transplantation (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who progress to high-grade hepatic encephalopathy (grade III or IV) should undergo endotracheal intubation (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Seizure activity should be treated with phenytoin and benzodiazepines with short half-lives. Prophylactic phenytoin is not recommended (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intracranial pressure (ICP) monitoring is recommended in ALF patients with high-grade hepatic encephalopathy, in centers with expertise in ICP monitoring, in patients awaiting and undergoing liver transplantation (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the absence of ICP monitoring, frequent (hourly) neurological evaluation is recommended to identify early evidence of intracranial hypertension (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the event of intracranial hypertension, a mannitol bolus (0.5-1.0 gm/kg body weight) is recommended as first-line therapy; however, the prophylactic administration of mannitol is not recommended (&lt;strong&gt;Grade II-2&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In ALF patients at highest risk for cerebral edema (serum ammonia &amp;gt;150 &amp;micro;M, grade 3/4 hepatic encephalopathy, acute renal failure, requiring vasopressors to maintain mean arterial pressure [MAP]), the prophylactic induction of hypernatremia with hypertonic saline to a sodium level of 145-155 mEq/L is recommended (&lt;strong&gt;Grade I&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Short-acting barbiturates and the induction of hypothermia to a core body temperature of 34-35&amp;ordm;C may be considered for intracranial hypertension refractory to osmotic agents as a bridge to liver transplantation (&lt;strong&gt;Grade II-3&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Corticosteroids should not be used to control elevated ICP in patients with ALF (&lt;strong&gt;Grade I&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Infection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;35&quot;&gt;&#xD;&#xA;    &lt;li&gt;Periodic surveillance cultures are recommended to detect bacterial and fungal pathogens as early as possible. Antibiotic treatment should be initiated promptly according to surveillance culture results at the earliest sign of active infection or deterioration (progression to high grade hepatic encephalopathy or elements of the systemic inflammatory response syndrome [SIRS]) (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prophylactic antibiotics and antifungals have not been shown to improve overall outcomes in ALF and therefore cannot be advocated in all patients, particularly those with mild hepatic encephalopathy (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Coagulopathy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;37&quot;&gt;&#xD;&#xA;    &lt;li&gt;Replacement therapy for thrombocytopenia and/or prolonged prothrombin time is recommended only in the setting of hemorrhage or prior to invasive procedures (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Bleeding&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;38&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with ALF in the intensive care unit should receive prophylaxis with histamine-2 receptor (H&lt;sub&gt;2&lt;/sub&gt;) blocking agents or proton pump inhibitors (or sucralfate as a second-line agent) for acid-related gastrointestinal bleeding associated with stress (&lt;strong&gt;Grade I&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hemodynamics and Renal Failure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;39&quot;&gt;&#xD;&#xA;    &lt;li&gt;Fluid resuscitation and maintenance of adequate intravascular volume are recommended on presentation in patients with ALF. The initial treatment of hypotension should be with intravenous normal saline (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If dialysis support is needed for acute renal failure, it is recommended that a continuous mode rather than an intermittent mode be used (&lt;strong&gt;Grade I&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary artery catheterization is rarely necessary in patients with ALF and is associated with significant morbidity. Instead, appropriate volume status should be ensured with a volume challenge (&lt;strong&gt;Grade III&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Systemic vasopressor support with agents such as norepinephrine should be administered in volume-refractory hypotension or to ensure adequate cerebral perfusion pressure (CPP). Vasopressin or terlipressin can be added to norepinephrine in norepinephrine-refractory cases, but should be used cautiously in severely encephalopathic patients with intracranial hypertension (&lt;strong&gt;Grade II-1&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Goals of circulatory support in patients with ALF are a MAP &amp;ge;75 mmHg and CPP 60-80 mmHg (&lt;strong&gt;Grade II&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Metabolic Concerns&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;44&quot;&gt;&#xD;&#xA;    &lt;li&gt;Metabolic homeostasis must be carefully maintained in ALF patients. Overall nutritional status as well as glucose, phosphate, potassium, and magnesium levels should be monitored frequently, with expeditious correction of derangements (&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Prognosis and Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 6 in the original guideline document for potentially helpful indicators of poor prognosis in patients with ALF and indications for orthotopic liver transplantation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prognosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;45&quot;&gt;&#xD;&#xA;    &lt;li&gt;Currently available prognostic scoring systems do not adequately predict outcome and determine candidacy for liver transplantation. Reliance entirely upon these guidelines is thus not recommended&amp;nbsp;&amp;nbsp;(&lt;strong&gt;Grade III&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;46&quot;&gt;&#xD;&#xA;    &lt;li&gt;Urgent hepatic transplantation is indicated in ALF where prognostic indicators suggest a high likelihood of death (&lt;strong&gt;Grade II-3&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Living donor or auxiliary liver transplantation may be considered in the setting of limited organ supply, but its use remains controversial (&lt;strong&gt;Grade II-3&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Liver Support Systems&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;48&quot;&gt;&#xD;&#xA;    &lt;li&gt;Currently available liver support systems are not recommended outside of clinical trials; their future in the management of ALF remains unclear (&lt;strong&gt;Grade II-1&lt;/strong&gt;).&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence on Which a Recommendation Is Based&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade I&lt;/strong&gt;: Randomized controlled trials&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-1&lt;/strong&gt;: Controlled trials without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-2&lt;/strong&gt;: Cohort or case-control analytic studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade II-3&lt;/strong&gt;: Multiple time series, dramatic uncontrolled experiments&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade III&lt;/strong&gt;: Opinions of respected authorities, descriptive epidemiology&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is specifically stated for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of acute liver failure (ALF)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Side effects from drugs &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects from procedures &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Refractory intracranial hypertension (ICH) and/or decreased cerebral perfusion pressure (CPP) are considered relative contraindications to liver transplantation in many centers because of concern about poor neurological recovery. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Many patients with acute liver failure (ALF) have medical or psychosocial contraindications to transplantation, including irreversible brain injury, underlying cardiovascular disease, infection/sepsis, alcohol or drug abuse, poorly controlled psychiatric disease, or inadequate family support. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who develop significant bleeding with platelet levels below approximately 50,000/mm&lt;sup&gt;3&lt;/sup&gt; should generally be transfused with platelets provided no contraindication (such as thrombotic thrombocytopenic purpura or heparin-induced thrombocytopenia) exists. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Intended for use by physicians, the recommendations in this document suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. This document has been designated as a Position Paper, since the topic contains more data based on expert opinion than on randomized controlled trials and thus is not considered to have the emphasis and certainty of a Practice Guideline. Nevertheless, it serves an important purpose of facilitating proper and high level patient care.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Mobile Device Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lee WM, Larson AM, Stravitz T. AASLD position paper: the management of acute liver failure: update 2011. Baltimore (MD): American Association for the Study of Liver Diseases; 2011 Sep. 26 p.  [224 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2005 May (revised 2011 Sep)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Association for the Study of Liver Diseases - Nonprofit Research Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Association for the Study of Liver Diseases (AASLD)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;AASLD does not accept corporate support for the development of practice guidelines. However, AASLD gratefully acknowledges the support of Genentech and Merck for providing independent medical education grants for mobile download applications for AASLD practice guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Practice Guidelines Committee of the American Association for the Study of Liver Diseases (AASLD)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Primary Authors&lt;/em&gt;: William M. Lee, MD; Anne M. Larson, MD; and R. Todd Stravitz, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Committee Members&lt;/em&gt;: Jayant A. Talwalkar, MD, MPH (&lt;em&gt;Chair&lt;/em&gt;); Anna Mae Diehl, MD (&lt;em&gt;Board Liaison&lt;/em&gt;); Adrian M. Di Bisceglie, MD, (&lt;em&gt;Board Liaison&lt;/em&gt;); Jeffrey H. Albrecht, MD; Gaurav Arora, MD; Hari S. Conjeevaram, MD, MS; Amanda DeVoss, MMS, PA-C; Hashem B. El-Serag, MD, MPH; Jose&amp;acute; Franco, MD; David A. Gerber, MD; Stephen A. Harrison, MD; Christopher Koh, MD; Kevin Korenblat, MD; Simon C. Ling, MBChB; Raphael B. Merriman, MD, MRCPI; Gerald Y. Minuk, MD; Robert S. O'Shea, MD; Michael K. Porayko, MD; Nancy Reau, MD; Adnan Said, MD; Benjamin L. Shneider, MD; and Tram T. Tran, MD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Potential conflict of interest: Dr. William Lee has advisory relationships with Eli Lilly, Cumberland, Novartis, Forest Labs and Gilead and receives research support from Bristol-Myers Squibb, Cumberland, Gilead, Globeimmune, Merck, Vertex, Novartis, Boehringer Ingelheim, Anadys and Siemens. Dr. Anne Larson and Dr. R. Todd Stravitz have nothing to report.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005 May;41(5):1179-97. [179 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf&quot; title=&quot;AASLD Web site&quot;&gt;American Association for the Study of Liver Diseases Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Association for the Study of Liver Diseases, 1729 King Street, Suite 200; Alexandria, VA 22314; Phone: 703-299-9766; Web site: &lt;a href=&quot;http://www.aasld.org&quot; title=&quot;AASLD Web site&quot;&gt;www.aasld.org&lt;/a&gt;; e-mail: &lt;a href=&quot;mailto:aasld@aasld.org&quot;&gt;aasld@aasld.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012 Mar;55(3):965-7. Available from the &lt;a href=&quot;http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf&quot; title=&quot;AASLD Web site&quot;&gt;American Association for the Study of Liver Diseases Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;This guideline is available as a Personal Digital Assistant (PDA) download via the APPRISOR&amp;trade; Document Viewer from &lt;a href=&quot;http://www.apprisor.com&quot; title=&quot;APPRISOR Document Viewer&quot;&gt;www.apprisor.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on July 11, 2005. This summary was updated by ECRI on December 7, 2005 following the U.S. Food and Drug Administration (FDA) advisory on NovoSeven. This summary was updated by ECRI Institute on May 1, 2009 following the U.S. Food and Drug Administration advisory on antiepileptic drugs. This summary was updated by ECRI Institute on July 26, 2010 following the U.S. Food and Drug Administration (FDA) advisory on Proton Pump Inhibitors (PPI). This NGC summary was updated by ECRI Institute on June 13, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the American Association for the Study of Liver Diseases' copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
